Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz
Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz
View: Text | PDF
Research Article Immunology Oncology

CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity

  • Text
  • PDF
Abstract

In many solid cancers, tumor-associated macrophages (TAM) represent the predominant myeloid cell population. Antigen (Ag) cross-presentation leading to tumor Ag–directed cytotoxic CD8+ T cell responses is crucial for antitumor immunity. However, the role of recruited monocyte-derived macrophages, including TAM, as potential cross-presenting cells is not well understood. Here, we show that primary human as well as mouse CD206+ macrophages are effective in functional cross-presentation of soluble self-Ag and non–self-Ag, including tumor-associated Ag (TAA), as well as viral Ag. To confirm the presence of cross-presenting TAM in vivo, we performed phenotypic and functional analysis of TAM from B16-F10 and CT26 syngeneic tumor models and have identified CD11b+F4/80hiCD206+ TAM to effectively cross-present TAA. We show that CD11b+CD206+ TAM represent the dominant tumor-infiltrating myeloid cell population, expressing a unique cell surface repertoire, promoting Ag cross-presentation and Ag-specific CD8+ T cell activation comparable with cross-presenting CLEC9A+ DCs (cDC1). The presence of cross-presenting CD206+ TAM is associated with reduced tumor burden in mouse syngeneic tumor models and with improved overall survival in cutaneous melanoma patients. Therefore, the demonstration of effective Ag cross-presentation capabilities of CD206+ TAM, including their clinical relevance, expands our understanding of TAM phenotypic diversity and functional versatility.

Authors

Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz

×

Figure 2

B16-F10 melanoma isolated CD206+ TAM are efficient in cross-presentation of soluble OVA Ag.

Options: View larger image (or click on image) Download as PowerPoint
B16-F10 melanoma isolated CD206+ TAM are efficient in cross-presentation...
(A) Timeline of the murine syngeneic tumor model studies, indicating inoculation of B16-F10 melanoma cells (day 0) and respective endpoints (day 21, rapid-growth tumors; day 24, delayed-growth tumors). (B) In vivo B16-F10 tumor growth curves by 2 groups identified as rapid-growth tumor (cyanine blue) and delayed-growth tumor (purple). (C) Bar diagram represents percentage of CD11b+F4/80dim (gray) and CD11b+F4/80hi (red) TAM analyzed in rapid- and delayed-growth tumors by flow cytometry. (D and E) Bar diagrams represent percentage (D) and mean fluorescence intensity (MFI) (E) of CD206+ cells from CD11b+F4/80dim (gray) and CD11b+F4/80hi (red) TAM analyzed in rapid- and delayed-growth tumors by flow cytometry. (F) Bar diagram represents percentage of CD8a+ T cells in indicated cell division peak upon coculture with TAM (CD11b+F4/80+) isolated from rapid-growth tumors (cyanine blue) or delayed-growth tumors (purple). (B–F) Data show mean ± SEM (n= 4 mice per group). Unpaired Student’s t test was used. For multiple comparisons Holm-Šídák test was performed (C–E). *P < 0.05, **P < 0.01, ***P < 0.001. Red asterisk indicate the statistical analysis of CD11b+F4/80hi cells between rapid and delayed tumor growth. Black asterisks indicate the statistical analysis of CD11b+F4/80dim cells between rapid and delayed tumor growth.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts